Oura Health Ltd. announced a filing to list its shares on the Nasdaq exchange, targeting a market debut as early as later this month. The company expects a valuation that exceeds the roughly $11 billion price tag from its $900 million funding round last year.
Founded in Finland in 2013 and now headquartered in San Francisco, Oura sells smart rings that monitor heart rate, temperature, sleep quality and other biometric signals. The devices retail for $349 to $499, while users can subscribe to a data‑access service for $5.99 a month or $69.99 annually.
In the nine months ended 30 June, Oura generated $1.21 billion in revenue, a 74 % increase year over year, and posted a net profit of $60.8 million, up from a $1.6 million profit in the prior year. Subscription services now serve about 5 million users, a figure that has doubled annually, and delivered gross margins of 89 % in the same period. Membership revenue reached $240.5 million, up 121 % YoY, while hardware sales accounted for roughly 80 % of total revenue. Users open the companion app an average of 3.5 times per day.
The latest Oura Ring 5, launched in May at $399, is 40 % smaller than its predecessor and tracks more than 50 health metrics, including blood oxygen and women's health indicators. Oura says it has amassed close to 42 billion hours of biometric data from its global user base, which is 72 % female, with 42 % aged 30‑45 and 31 % under 29.
